Gemcitabine

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Urologic Neoplasms

Conditions

Urologic Neoplasms, Carcinoma, Transitional Cell

Trial Timeline

Jan 1, 2004 → Sep 1, 2006

NCT ID

NCT00191971

About Gemcitabine

Gemcitabine is a phase 2 stage product being developed by Eli Lilly for Urologic Neoplasms. The current trial status is completed. This product is registered under clinical trial identifier NCT00191971. Target conditions include Urologic Neoplasms, Carcinoma, Transitional Cell.

What happened to similar drugs?

0 of 1 similar drugs in Urologic Neoplasms were approved

Approved (0) Terminated (0) Active (1)

🔄Mirabegron + Solifenacin succinateAstellas PharmaPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (7)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00337259	Phase 2	Terminated	Jun 1, 2006	Mar 1, 2009	Non-Hodgkin's Lymphoma
NCT00191711	Phase 2	Completed	Feb 1, 2004	Oct 1, 2005	Superficial Bladder Cancer
NCT00191971	Phase 2	Completed	Jan 1, 2004	Sep 1, 2006	Urologic Neoplasms
NCT00390182	Phase 1/2	Completed	Oct 1, 2003	May 1, 2011	Gastrointestinal Neoplasms
NCT00491114	Phase 2	Completed	Jul 1, 2003	Aug 1, 2004	Bladder Neoplasms
NCT02046304	Phase 1	Completed	Dec 1, 2001	Mar 1, 2015	Sarcoma
NCT00146276	Phase 3	UNKNOWN	Jul 1, 2000	—	Bladder Cancer

Competing Products

16 competing products in Urologic Neoplasms

See all competitors

Product	Company	Stage	Hype Score
pemetrexed + cisplatin	Eli Lilly	Phase 1/2	32
Mirabegron + Solifenacin succinate + Placebo	Astellas Pharma	Phase 2	35
Mirabegron + Solifenacin succinate	Astellas Pharma	Phase 3	40
pemetrexed	Eli Lilly	Phase 2	35
ALIMTA + gemcitabine	Eli Lilly	Phase 2	35
BBI503	Sumitomo Pharma	Phase 2	27
Pembrolizumab Injection [Keytruda]	Merck	Phase 2	42
Carboplatin/Paclitaxel + Pembrolizumab	Merck	Phase 2	42
zoledronic acid	Novartis	Phase 2	27
mycophenolate mofetil	Roche	Phase 1	29
Cetuximab + Paclitaxel	Bristol Myers Squibb	Phase 2	35
Nivolumab + Relatlimab	Bristol Myers Squibb	Phase 2	42
CBT101 + Placebo	Brain Biotech	Phase 1	26
OGX-427 600 mg + OGX-427 1000 mg + Placebo + Gemcitabine + Cisplatin + Carboplatin	Achieve Life Sciences	Phase 2	25
S-8184 Paclitaxel Injectable Emulsion + Experimental Arm: TOCOSOL Paclitaxel	Achieve Life Sciences	Phase 2	25
Stem Cell	Brain Biotech	Phase 1	11